Stocks
Ascendis Pharma A/SASND
NASDAQHealthcareBiotechnology$225.98-1.32%
Price as of · delayed, not real-time
Focused on developing innovative endocrine rare disease therapies, this biopharmaceutical company has gained investor attention for its TransCon technology platform. Its lead product, Skytrofa for pediatric growth hormone deficiency, represents a potential blockbuster in a niche market with limited competition.
Market Cap: $13.9B52W Range: $124.06 – $248.60
Congressional Interest in Ascendis Pharma A/S (ASND)
1 member of Congress has disclosed 3 trades in Ascendis Pharma A/S (ASND), a Healthcare company. The buy/sell breakdown shows 2 purchases versus 1 sale, indicating net buying interest from lawmakers. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
Total Disclosures
3
Unique Politicians
1
Buys
2
Sells
1
Who in Congress Is Trading ASND?
| Date | Politician | Type | Amount |
|---|---|---|---|
| 2018-10-05 | Gary Palmer | sell | $1K – $15K |
| 2018-08-06 | Gary Palmer | buy | $1K – $15K |
| 2018-07-12 | Gary Palmer | buy | $1K – $15K |